Physician profile
Shane T Fejfar
NPI 1669437695
$597.56
in general payments reported to CMS, 2019-2025
13 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.25 · 2020: $52.06 · 2022: $88.15 · 2023: $69.25 · 2024: $113 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $237.44 | 2019-2025 | Ortholoc 3di, Inspace, Augment Injectable |
| Smith+Nephew, INC. | $77.18 | 2022-2025 | Grafix Pl, Stravix Pl |
| Kerecis Limited | $45.32 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Acumed LLC | $41.93 | 2025 | Acumed |
| Titan Surgical Group, LLC | $37.43 | 2023-2025 | |
| Treace Medical Concepts, INC. | $27.27 | 2025 | |
| Medacta USA, INC. | $25.66 | 2022 | |
| Aesculap, INC. | $24.62 | 2023 | Elan 4 |
| Convatec INC. | $22.62 | 2024 | |
| Heron Therapeutics, INC. | $17.70 | 2022 | |
| Solventum Corporation | $15.24 | 2025 | Prevena |
| Sonex Health, INC. | $12.83 | 2020 | |
| Abbvie INC. | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Fejfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.